BRAF V600E突变与甲状腺乳头状癌临床病理相关性研究

赵荧; 王鸿雁; 王春宝; 牛蔓; 汪园园; 李晓锋

doi:10.13201/j.issn.1001-1781.2018.19.007

BRAF V600E突变与甲状腺乳头状癌临床病理相关性研究

- 1. 西安交通大学第一附属医院病理科(西安, 710061);
- 2. 西安市第四医院病理科

详细信息

通讯作者: 王鸿雁, E-mail:whycc0320@126.com

中图分类号: R736.1

收稿日期: 2018-07-19

Analysis of clinicopathological characteristics of papillary thyroid carcinoma and BRAF V600E gene mutation

- 1 Department of Pathology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China;
- 2 Department of Pathology, the Fourth Hospital of Xi'an

More Information

Corresponding author: WANG Hongyan, E-mail: whycc0320@126.com

Received Date: 19 July 2018

摘要

摘要: 目的: 研究BRAF V600E突变与甲状腺乳头状癌(PTC)临床病理特征的相关性,探讨PTC组织BRAF V600E突变检测的应用价值。方法: 采用qPCR方法对108例PTC患者及30例对照组织进行BRAF V600E突变检测,回顾PTC突变型组和野生型组患者的临床病理资料,使用SPSS 21.0软件进行统计学分析。结果: 对照组未检测到BRAF V600E突变。108例PTC患者BRAF V600E突变率为72.20%。突变型组患者平均年龄大于野生型组,差异有统计学意义(P<0.05)。BRAF V600E突变与PTC组织亚型有关,与中央区淋巴结转移有关,差异有统计学意义(P<0.05)。与肿瘤直径、性别、多灶性、癌灶部位、伴随疾病、颈侧区淋巴结转移、被膜侵犯及TNM分期无关(P>0.05)。结论: BRAF V600E突变对PTC预后判断的价值尚待研究,相比于预后判断,对PTC的病理诊断价值更加显著。
- 甲状腺肿瘤 /
- BRAFV600E基因 /
- 病理学检查
Abstract: Objective: To study the correlation between the BRAF V600E mutation and the clinicopathological features of papillary thyroid carcinoma(PTC), and to explore the application value of BRAF V600E mutation in PTC. Method: The BRAF V600E gene mutation was detected in 108 PTC cases and 30 control cases by qPCR. The results were statistically analyzed by using SPSS 21.0 software. Result: The BRAF V600E mutation was absent in the control group. The BRAF V600E mutation rate was 72.20% in 108 PTC cases. Compared with patients with wild-type, the mean age of patients with the mutant BRAF V600E was significantly older(P<0.05). BRAF V600E mutations were associated with PTC tissue subtypes and central area lymph node metastasis(P<0.05). BRAF V600E mutations were not correlated with tumor diameter, patient gender, multifocality, tumor site, concomitant disease, lymph node metastasis in side region of neck, capsule invasion, and TNM staging(P>0.05). Conclusion: The value of BRAF V600E mutation in the prognosis of PTC remains to be studied. BRAF V600E mutation is of value for pathological diagnosis of PTC.
- thyroid neoplasms /
- BRAF V600E gene /
- pathological examination

HTML全文

参考文献(21)

[1]	KONDO T, EZZAT S, ASA S L.Pathogenetic mechanisms in thyroid follicular-cell neoplasia[J].Nat Rev Cancer, 2006, 6:292-306.
[2]	XING M.BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications[J].Endocr Rev, 2007, 28:742-762.
[3]	LIU C, CHEN T, LIU Z.Associations between BRAF (V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma:a meta-analysis[J].World J Surg Oncol, 2016, 14:241-241.
[4]	LIU X, YAN K, LIN X, et al.The association between BRAF (V600E) mutation and pathological features in PTC[J].Eur Arch Otorhinolaryngol, 2014, 271:3041-3052.
[5]	TROVISCO V, SOARES P, PRETO A, et al.Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinomahistotype and patients'age but not with tumour aggressiveness[J].Virchows Arch, 2005, 446:589-595.
[6]	LAM K Y.Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours[J].Endocrine Pathology, 2017, 28 (3):213-227.
[7]	TUTTLE R M, HAUGEN B, PERRIER N D.Updated American Joint Committee on Cancer/TumorNode-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition):What Changed and Why[J]?Thyroid, 2017, 27:751-756.
[8]	HARA H, FULTON N, YASHIRO T, et al.N-ras mutation:an independent prognostic factor for aggressiveness of papillary thyroid carcinoma[J].Surgery, 1994, 116:1010-1016.
[9]	OISHI N, KONDO T, NAKAZAWA T, et al.Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan[J].Endocr Pathol, 2017, 28:103-111.
[10]	NUCERA C, PONTECORVI A.Clinical outcome, role of BRAF (V600E), and molecular pathways in papillary thyroid microcarcinoma:is it an indolent cancer or an early stage of papillary thyroid cancer[J]?Front Endocrinol (Lausanne), 2012, 3:33-33.
[11]	NAVARRO-LOCSIN C G, CHANG A M, DAROY M L, et al.Clinical and histopathological profile of BRAF V600E mutation in conventional papillary thyroid carcinoma in a Filipino population[J].Malays J Pathol, 2016, 38:141-148.
[12]	HARDEE S, PRASAD M L, HUI P, et al.Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma[J].Pediatr Dev Pathol, 2017, 20:206-212.
[13]	CZARNIECKA A, OCZKO-WOJCIECHOWSKA M, BARCZYNSKI M.BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence[J].Gland Surg, 2016, 5:495-505.
[14]	高庆军, 张伟, 王南鹏, 等.BRAF- (V600E) 突变和cN0期甲状腺乳头状癌淋巴结转移相关性研究[J].临床耳鼻咽喉头颈外科杂志, 2015, 29 (23):2048-2052.
[15]	CZARNIECKA A, KOWAL M, RUSINEK D, et al.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors[J].PLoS One, 2015, 10:e132821.
[16]	NAIR C G, BABU M, BISWAS L, et al.Lack of Association of B-type Raf Kinase V600E Mutation with High-risk Tumor Features and Adverse Outcome in Conventional and Follicular Variants of Papillary Thyroid Carcinoma[J].Indian J Endocrinol Metab, 2017, 21:329-333.
[17]	HENKE L E, PFEIFER J D, MA C, et al.BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma[J].Cancer Med, 2015, 4:791-799.
[18]	陶久梅, 王艳, 朱姝, 等.甲状腺乳头状癌颈部淋巴结转移规律及影响因素分析[J].临床耳鼻咽喉头颈外科杂志, 2014, 28 (12):859-861.
[19]	陈征, 董汉华, 叶真.中央区淋巴结清扫在甲状腺乳头状癌手术中的价值[J].临床耳鼻咽喉头颈外科杂志, 2015, 29 (2):120-122.
[20]	FRANGOS S, IAKOVOU I P, MARLOWE R J, et al.Acknowledging gray areas:2015 vs.2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients[J].Eur J Nucl Med Mol Imaging, 2017, 44:185-189.
[21]	BOERNER S L, ASA S L, 王炜, 等.甲状腺病理活检解读[M].北京:科学技术出版社, 2015:126-129.